Lp(a) and Extracoronary Vascular Disease Risk

Here’s a summary of the key ⁣findings from the provided text regarding Lp(a) and cardiovascular risk:

Lp(a) Levels & Risk: Higher levels of Lp(a)‌ are associated with increased risk of‌ several cardiovascular events.‌ Specifically, the study found associations with:
‍
Incident Peripheral Artery ⁤Disease (PAD)
Incident ⁣Carotid ⁤Stenosis
‌
‌ Major Adverse Limb Events (in those with PAD)
Progression to Stroke (though this association wasn’t statistically ‌significant in the study)

Quantified‌ Risk increases:
For every 75 nmol/L increase⁣ in Lp(a), the risk of PAD increased ⁤by 18% (HR = 1.18).
For every 75 nmol/L increase in Lp(a), the risk of carotid stenosis increased by 17% (HR = 1.17).
⁣ participants with PAD and Lp(a) ≥ 150 nmol/L had a 57% increased risk of major adverse limb events (HR =⁢ 1.57).

Residual‍ Risk & Future Research: The researchers highlight that despite current treatments for atherosclerotic vascular disease, a significant risk remains, suggesting Lp(a) could be a valuable biomarker for ‌predicting risk ‍and perhaps a target for new therapies.

* Disclosures: One‍ author has extensive financial ties to numerous pharmaceutical and⁤ biotechnology companies involved in cardiovascular research.